2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3200

Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model
Abstract Number: 1752

Characterization of Epitopes Identified with Cerebral Vasculature Injury
Abstract Number: 2832

Characterization of Leukocyte Subsets in Ankylosing Spondylitis Patients
Abstract Number: 1380

Characterization of Lymphocytes Subsets in Peripheral Blood of Untreated IgG4-Related Disease Patients
Abstract Number: 2825

Characterization of Mesenchymal Stem Cells Generated from Axial Spondyloarthritis Patient-Derived Induced Pluripotent Stem Cells
Abstract Number: 1436

Characterization of Patient Reported Pain Medication in Early Vs. Established Rheumatoid Arthritis
Abstract Number: 408

Characterization of Pediatric Systemic Lupus Erythematosus with Acquired Angioedema
Abstract Number: 673

Characterization of Psoriatic Arthritis [Psa] in a Large, Integrated Health Plan: Demographics, Referral Patterns and Care Management
Abstract Number: 1372

Characterization of Synovial Mast Cells in Knee Osteoarthritis: Association with Clinical Parameters
Abstract Number: 3015

Characterization of the Profibrotic/Antifibrotic Profile of microRNA Contained in Exosomes Isolated from Cultured Normal Human Dermal and Lung Microvascular Endothelial Cells Undergoing Endothelial Mesenchymal Transition in Vitro
Abstract Number: 2464

Characterization of the Serum Anti-Citrullinated Protein Antibody Profile in Juvenile Idiopathic Arthritis: Association with Oral Health
Abstract Number: 3022

Characterizing a Novel Gene, Mosaic, and Its Role in Mediating a Multisystem Autoimmunity
Abstract Number: 3212

Characterizing the Effects of the G-CSF-R Coding rs13377964 SNP Located within Murine Lupus Susceptibility Locus Sle2c2
Abstract Number: 2549

Characterizing the RPTPσ Mediated Proteoglycan Switch As a Target for Rheumatoid Arthritis Therapy
Abstract Number: 1069

Child’s HLA-DRB1 Genotype Increases Maternal Risk of Systemic Lupus Erythematosus: Results from the Mother-Child Immunogenetic Study in Autoimmunity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].